ESMO 2026 - Liste complète des programmes (15)

Les Drs Jamil Asselah, Arif Awan et François Panet discutent des temps forts de la première journée de l’ESMO 2026 en cancer du sein : NATALEE, TALENT, NSABP B-42, ADC émergents et implications possibles pour la pratique clinique.

Le Dr Jean-François Boileau présente les résultats d’IRM de DESTINY-Breast11 : réponse tumorale sous T-DXd suivi de THP et limites de l’IRM pour prédire la réponse pathologique complète dans le cancer du sein précoce HER2+.

Les Drs Jamil Asselah et François Panet partagent les temps forts du jour 2 à Madrid : ADC et métastases cérébrales, immunothérapie, VIKTORIA-1 et postMONARCH, avec leurs perspectives sur la pratique clinique.

Dr. Sara Hurvitz reviews TALENT, evaluating neoadjuvant T-DXd in HR-positive, HER2-low early breast cancer, with pCR rates below 10% and exploratory biomarker findings that may inform future patient selection.

Could immunotherapy have a role in endocrine-resistant HR+/HER2-negative advanced breast cancer? Dr. Hope Rugo shares the KEYNOTE-B49 findings and what they could mean for patient selection and clinical practice.

Dr. Sara Tolaney explores the evERA biomarker analysis, examining ctDNA, ESR1 mutations and what they could tell us about giredestrant plus everolimus after CDK4/6 inhibitor progression in HR-positive metastatic breast cancer.

After CDK4/6 progression, the search for new options continues. Dr. Antonio Giordano takes a closer look at FOURLIGHT-1 and atirmociclib plus fulvestrant in HR+/HER2-negative metastatic breast cancer.

Treatment through the patient’s eyes. Dr. Gustavo Werutsky discusses the lidERA patient-reported outcomes, focusing on quality of life, joint pain and tolerability with adjuvant giredestrant in ER+/HER2-negative early breast cancer.

Drs. Christine Brezden-Masley and Christine Simmons bring two Canadian perspectives to a discussion on selective CDK4 inhibition, NATALEE, brain metastases and emerging ADCs in breast cancer.

Dr. Paolo Tarantino shares his ESMO highlights on selective CDK4 inhibitors, immunotherapy and emerging ADCs, alongside CHARISMA and the search for biomarkers to guide treatment selection and understand resistance.

Pour clore l’ESMO 2026, les Drs Rami Younan et François Panet reviennent sur les temps forts en cancer du sein : séquençage des ADC, métastases cérébrales et leptoméningées, décisions thérapeutiques et accès aux traitements au Canada.

Entre résultats d’essais et décisions en clinique, la Dre Nathalie LeVasseur aborde FOURLIGHT-1, postMONARCH et le rôle des biomarqueurs après progression sous CDK4/6 dans le cancer du sein métastatique RH+/HER2−.

Tracking treatment through blood samples. Dr. Carlos Barcenas introduces B-STRONGER-I and explores ultra-sensitive ctDNA monitoring during neoadjuvant therapy, with a look at future directions in early triple-negative breast cancer.

Progress in metastatic breast cancer brings new responsibilities for care. Dr. Christine Simmons offers a Canadian reflection on quality of life, oncology capacity, monitoring and the cost of new treatments.

Dr. Hongxia Wang of Fudan University Shanghai Cancer Center takes us inside a phase 1/2 study of a B7-H3-targeting ADC in advanced breast cancer, exploring its design and the next steps in clinical development.

The postMONARCH story continues. Dr. Kevin Kalinsky puts the final overall survival analysis into perspective, alongside updated efficacy and safety data, in advanced breast cancer after progression on a CDK4/6 inhibitor.

Les tests génomiques dans le contexte égyptien. Le Dr Hatem Azim explore le rôle d’Oncotype DX dans les décisions thérapeutiques en cancer du sein, auprès d’une population peu représentée dans la recherche, et les enjeux d’accès au test.

A blood-based perspective on breast cancer follow-up. Dr. Yukinori Ozaki examines JCOG1204A1 and the potential role of ctDNA monitoring in detecting recurrence after surgery.

Two Canadian colleagues, one lively exchange. Drs. Christine Brezden-Masley and Mita Manna discuss emerging ADCs, treatment sequencing and brain metastases, connecting ESMO breast cancer research with questions facing Canadian clinicians.

Addressing an urgent unmet need in HER2-positive breast cancer, Dr. Kamran Ahmed presents INSPIRE-LM, a phase II trial exploring radiation followed by intrathecal trastuzumab and pertuzumab for leptomeningeal metastases.